These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3972760)

  • 41. Cefotaxime in the treatment of prophylaxis of surgical infections.
    Wittmann DH; Jones RN; Malledant J; Privitera G
    J Chemother; 1997 May; 9 Suppl 2():19-33. PubMed ID: 9248973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ampicillin/sulbactam compared with cefotaxime in the treatment of lower respiratory tract infections of bacterial etiology.
    Jauregui L; Minns P; Hageage G
    Adv Ther; 1995; 12(1):62-71. PubMed ID: 10150322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ceftriaxone compared with cefotaxime for serious bacterial infections.
    Smith CR; Petty BG; Hendrix CW; Kernan WN; Garver PL; Fox K; Beamer A; Carbone K; Threlkeld M; Lietman PS
    J Infect Dis; 1989 Sep; 160(3):442-7. PubMed ID: 2668428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of cefotaxime in gram-negative meningitis.
    LeFrock JL; Molavi A; Smith B; Black P; Rosenberg M; Rolston K; Brodner R; Chandrasekar P; Henao L; Kannangara DW
    Neurosurgery; 1984 Nov; 15(5):679-82. PubMed ID: 6095133
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cefotaxime therapy of serious bacterial infection in adults.
    Mullaney DT; John JF
    Antimicrob Agents Chemother; 1982 Mar; 21(3):421-5. PubMed ID: 6285810
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapy of lower respiratory tract infections: a comparison of ceftriaxone and cefotaxime.
    Barradas P; Zamith M; Videira W; Cardosa T; Marques RA; Avila R
    Chemotherapy; 1989; 35 Suppl 2():33-40. PubMed ID: 2612238
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical studies of cefotaxime in infections in internal medicine].
    Kawasaki H; Suou T; Watanabe K; Yoshida K; Sasaki H; Kishimoto Y; Sugihara T; Ishitobi S; Kanno S; Tsuruhara I
    Jpn J Antibiot; 1984 Sep; 37(9):1714-28. PubMed ID: 6096586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
    Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of cefotaxime in the treatment of infections associated with hematologic diseases].
    Kaneko H; Masaki T; Yamaguchi R; Takahashi N; Umeda M; Shirai T
    Jpn J Antibiot; 1983 Sep; 36(9):2502-14. PubMed ID: 6317914
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A clinical and laboratory study of China-made cefotaxime].
    Niu WW; Wang QN; Lin YH
    Zhonghua Nei Ke Za Zhi; 1985 Nov; 24(11):641-5, 700. PubMed ID: 3833501
    [No Abstract]   [Full Text] [Related]  

  • 51. Moxalactam therapy of difficult infections in patients with serious underlying conditions.
    Mogabgab WJ; Bauman DC; LaCorte WF; Pollock B; Pauling B; Beville RB; Holmes BJ
    J Int Med Res; 1983; 11(5):269-78. PubMed ID: 6642067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime.
    Toledo C; Salmerón JM; Rimola A; Navasa M; Arroyo V; Llach J; Ginès A; Ginès P; Rodés J
    Hepatology; 1993 Feb; 17(2):251-7. PubMed ID: 8428722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cefotaxime in the treatment of lower respiratory tract infections.
    Beumer HM; Veldkamp J; Deleers L
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):605-10. PubMed ID: 6321367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cefotaxime therapy for serious infections.
    Tanphaichitra D; Wanvarie S; Srimuang S
    J Med Assoc Thai; 1984 Feb; 67(2):108-10. PubMed ID: 6330259
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical experience with cefotaxime with particular reference to septicaemia.
    McKendrick MW
    Ir Med J; 1982 May; 75(5 Suppl):8-9. PubMed ID: 6284677
    [No Abstract]   [Full Text] [Related]  

  • 56. Piperacillin plus amikacin versus cefotaxime plus amikacin in neutropenic and feverish patients with malignant hemopathies.
    Pavone V; Specchia G; Guarini A; Coniglio M; Iaculli L; Girardi F; Colucci A; Liso V
    Chemioterapia; 1988 Oct; 7(5):330-5. PubMed ID: 3224402
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical effects of cefodizime in severe infections complicated with hematological diseases. Hanshin Infection Study Group].
    Teshima H; Masaoka T; Hiraoka A; Horiuchi A; Hasegawa H; Kitani T; Tagawa S; Yonezawa T; Kanayama Y; Take H
    Jpn J Antibiot; 1992 Oct; 45(10):1295-304. PubMed ID: 1479681
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A study of cefotaxime versus netilmicin versus netilmicin and cefotaxime in serious infections.
    Sen RA; Keaney MG; Ganguli LA
    J Chemother; 1989 Jul; 1(4 Suppl):652-4. PubMed ID: 16312576
    [No Abstract]   [Full Text] [Related]  

  • 59. [Clinical evaluation of cefozopran for infections associated with hematological malignancies].
    Sasai Y; Iwai T; Tamura A; Nakazawa N; Ueda Y; Kaneko H; Horiike S; Yokota S; Taniwaki M; Kashima K; Misawa S; Tsuda S; Ohgawara Y
    Jpn J Antibiot; 1998 Aug; 51(8):501-8. PubMed ID: 9836122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Value of cefotaxime in gram-negative bacterial meningitis. Apropos of 3 developmental forms in neonates and infants].
    Sarlangue J; Megraud F; Nelson JR; Martin C
    Pediatrie; 1984 Dec; 39(8):645-51. PubMed ID: 6100207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.